Education
About Us
Working with TipRanks
Follow Us
Transgene SA (FR:TNG)
:TNG
Total Valuation
Transgene has a market cap or net worth of €170.81M. The enterprise value is €127.76M.
Market Cap€170.81M
Enterprise Value€127.76M
Share Statistics
Transgene has 132,753,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding132,753,360
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Transgene’s return on equity (ROE) is -2.23 and return on invested capital (ROIC) is -125.68%.
Return on Equity (ROE)-2.23
Return on Assets (ROA)-0.81
Return on Invested Capital (ROIC)-125.68%
Return on Capital Employed (ROCE)-1.26
Revenue Per Employee44.12K
Profits Per Employee-235.91K
Employee Count144
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Transgene is ―. Transgene’s PEG ratio is -0.07.
PE Ratio―
PS Ratio12.49
PB Ratio5.22
Price to Fair Value5.22
Price to FCF-2.98
Price to Operating Cash Flow-6.43
PEG Ratio-0.07
Income Statement
In the last 12 months, Transgene had revenue of 6.35M and earned -33.97M in profits. Earnings per share was -0.29.
Revenue6.35M
Gross Profit-27.93M
Operating Income-35.66M
Pretax Income-40.02M
Net Income-33.97M
EBITDA-26.65M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -23.89M and capital expenditures -1.34M, giving a free cash flow of -25.23M billion.
Operating Cash Flow-23.89M
Free Cash Flow-25.23M
Free Cash Flow per Share-0.19
Dividends & Yields
Transgene pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change59.01%
50-Day Moving Average1.16
200-Day Moving Average0.85
Relative Strength Index (RSI)65.80
Average Volume (3m)129.86K
Important Dates
Transgene upcoming earnings date is Nov 4, 2025, During Market Hours (Confirmed).
Last Earnings DateSep 16, 2025
Next Earnings DateNov 4, 2025
Ex-Dividend Date―
Financial Position
Transgene as a current ratio of 1.48, with Debt / Equity ratio of -848.14%
Current Ratio1.48
Quick Ratio1.48
Debt to Market Cap0.13
Net Debt to EBITDA0.24
Interest Coverage Ratio-21.21
Taxes
In the past 12 months, Transgene has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Transgene EV to EBITDA ratio is -2.74, with an EV/FCF ratio of -2.74.
EV to Sales11.50
EV to EBITDA-2.74
EV to Free Cash Flow-2.74
EV to Operating Cash Flow-3.10
Balance Sheet
Transgene has €16.77M in cash and marketable securities with €30.57M in debt, giving a net cash position of -€13.80M billion.
Cash & Marketable Securities€16.77M
Total Debt€30.57M
Net Cash-€13.80M
Net Cash Per Share-€0.10
Tangible Book Value Per Share€0.13
Margins
Gross margin is -512.90%, with operating margin of -561.28%, and net profit margin of -534.72%.
Gross Margin-512.90%
Operating Margin-561.28%
Pretax Margin-629.89%
Net Profit Margin-534.72%
EBITDA Margin-419.52%
EBIT Margin-439.68%
Analyst Forecast
The average price target for Transgene is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast111.76%
EPS Growth Forecast-22.45%